NBCD is dedicated to clinical drug development in Osteoarthritis. We specialize in design and execution of clinical trials within both pain and DMOAD compounds for osteoarthritis. We are experts in placebo response mitigation and selecting the right patients. Our background makes us experts in precision medicine using various biomarker approaches. We support our biotech and pharmaceutical clients advance their osteoarthritis compounds through all clinical development phases.
NBCD has more than 25 years’ experience in biomarker development and clinical trials and has particularly acquired extensive expertise in rheumatology. Combining our experience in preclinical and clinical research enables us to help provide a faster and smarter detection of signals of the potential clinical viability of drug candidates.
We tailor our unique solutions to our clients’ needs. As a privately owned, specialized company we are able to make decisions swiftly, leverage cross-functional synergies and quickly adapt the organization to best accommodate current and future needs.
NBCD liaises with our pharmaceutical and biotech clients to identify projects most suitable for clinical development. We assist our clients in understanding a compound’s mode of action and optimal dosing. Our experience in clinical and preclinical research allows us to help provide a faster and smarter detection of signals of clinical viability of future treatment options.
As a science-driven and specialized company we proudly publish more than 50 scientific papers annually in high-impact journals.
Rheumatology constitutes the largest part of our research legacy at Nordic Bioscience as we have completed multiple clinical phase I-III trials in osteoporosis and osteoarthritis. Our proprietary biomarkers are used to detect early signals of efficacy and segregation of phenotypes to enable the development of truly Precision Medicine.
Our expertise includes:
As a science-driven and specialized company we proudly publish more than 40 scientific papers annually in high-impact journals.